193 related articles for article (PubMed ID: 36637997)
21. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization of an intact p53 pathway subtype in high-grade serous ovarian cancer.
Hayano T; Yokota Y; Hosomichi K; Nakaoka H; Yoshihara K; Adachi S; Kashima K; Tsuda H; Moriya T; Tanaka K; Enomoto T; Inoue I
PLoS One; 2014; 9(12):e114491. PubMed ID: 25460179
[TBL] [Abstract][Full Text] [Related]
23. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
[TBL] [Abstract][Full Text] [Related]
24. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
25. Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Chen J; Shi X; Xiao L; Li Z; Li Z; Sun L
Cancer Med; 2022 Oct; 11(20):3761-3770. PubMed ID: 35434908
[TBL] [Abstract][Full Text] [Related]
26. Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
Herrington CS; Oswald AJ; Stillie LJ; Croy I; Churchman M; Hollis RL
Br J Cancer; 2024 Feb; 130(2):327-335. PubMed ID: 38097740
[TBL] [Abstract][Full Text] [Related]
27. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
28. Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer.
Zhang W; Liu Y; Sun N; Wang D; Boyd-Kirkup J; Dou X; Han JD
Cell Rep; 2013 Aug; 4(3):542-53. PubMed ID: 23933257
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers.
Chan DW; Lam WY; Chen F; Yung MMH; Chan YS; Chan WS; He F; Liu SS; Chan KKL; Li B; Ngan HYS
Clin Epigenetics; 2021 Jul; 13(1):142. PubMed ID: 34294135
[TBL] [Abstract][Full Text] [Related]
30. Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer.
Wang Y; Xie H; Chang X; Hu W; Li M; Li Y; Liu H; Cheng H; Wang S; Zhou L; Shen D; Dou S; Ma R; Mao Y; Zhu H; Zhang X; Zheng Y; Ye X; Wen L; Kee K; Cui H; Tang F
Cancer Res; 2022 Nov; 82(21):3903-3916. PubMed ID: 35969151
[TBL] [Abstract][Full Text] [Related]
31. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
[TBL] [Abstract][Full Text] [Related]
32. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
[TBL] [Abstract][Full Text] [Related]
33. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
34. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
[TBL] [Abstract][Full Text] [Related]
35. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
Zhang Q; Wang C; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):368-374. PubMed ID: 30448260
[TBL] [Abstract][Full Text] [Related]
36. Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.
Bateman NW; Jaworski E; Ao W; Wang G; Litzi T; Dubil E; Marcus C; Conrads KA; Teng PN; Hood BL; Phippen NT; Vasicek LA; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Darcy KM; Conrads TP
J Proteome Res; 2015 Apr; 14(4):1900-10. PubMed ID: 25748058
[TBL] [Abstract][Full Text] [Related]
37. Assessing the clinical utility of multi-omics data for predicting serous ovarian cancer prognosis.
Zhang Z; Wei Z; Zhao L; Gu C; Meng Y
J Obstet Gynaecol; 2023 Dec; 43(1):2171778. PubMed ID: 36803381
[TBL] [Abstract][Full Text] [Related]
38. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
39. Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.
Sun J; Yan C; Xu D; Zhang Z; Li K; Li X; Zhou M; Hao D
Br J Cancer; 2022 Jun; 126(11):1570-1580. PubMed ID: 35017656
[TBL] [Abstract][Full Text] [Related]
40. Ovarian cancer and the evolution of subtype classifications using transcriptional profiling†.
Cook DP; Vanderhyden BC
Biol Reprod; 2019 Sep; 101(3):645-658. PubMed ID: 31187121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]